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parameters were assessed.  Results: At rest, the mean serum 
level of NT-proBNP was 1,278  8 998 pg/ml. The mean level 
of NT-proBNP at maximal exercise was increased (1,592  8 
1,219 pg/ml), whereas serum levels decreased slightly during 
recovery (1,518  8 1,170 pg/ml). The relative increase of se-
rum NT-proBNP during exercise correlated with pulmonary 
vascular resistance (r = 0.45; p = 0.026) and cardiac output
(r = –0.5; p = 0.015).  Conclusions: In this study, we demon-
strated acute changes in NT-proBNP levels due to physical 
exercise in a small group of patients with precapillary pulmo-
nary hypertension. Our results also confirm the predominant 
usefulness of NT-proBNP as an intraindividual parameter of 
right heart load.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Precapillary pulmonary hypertension is a rare disease 
characterized by an elevated pulmonary artery pressure 
exceeding 25 mm Hg at rest  [1] . Persistent elevation of 
pulmonary vascular resistance of different causes induc-
es right ventricular dysfunction resulting in a decrease in 
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 Abstract 
 Background: N-terminal pro-brain natriuretic peptide (NT-
proBNP) is secreted by cardiac ventricular myocytes upon 
pressure and volume overload and is a prognostic marker to 
monitor the severity of precapillary pulmonary hyperten-
sion and the extent of right heart failure.  Objectives: The 
impact of physical exercise on NT-proBNP levels in patients 
with left heart disease was demonstrated previously. No 
data regarding patients with isolated right heart failure and 
the influence of acute exercise on NT-proBNP serum levels 
exist.  Methods: Twenty patients with precapillary pulmo-
nary hypertension were examined. Hemodynamic parame-
ters were measured during right heart catheterization. Se-
rum NT-proBNP of patients was measured at rest, after a 
6-min walking test, during ergospirometry and during re-
covery, all within 7 h. Significant differences in sequential 
NT-proBNP values, relative changes compared to values at 
rest and the correlation between NT-proBNP and obtained 
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cardiac output and progressive right heart failure, even-
tually leading to death. Echocardiography and right heart 
catheterization are used to assess the extent of right ven-
tricular dysfunction and the severity of pulmonary hy-
pertension in patients  [2] . Biomarkers correlating with 
the extent of heart failure, such as the N-terminal pro-
brain natriuretic peptide (NT-proBNP), have been used 
to avoid frequent invasive procedures in patients with 
pulmonary hypertension  [3, 4] .
 NT-proBNP is a cleavage product of the neurohor-
mone B-type natriuretic peptide (BNP) synthesized in 
the cardiac ventricles and released upon ventricular myo-
cyte stretch  [5] . The half-life of NT-proBNP is 120 min 
before it is degraded by neutral endopeptidase and ex-
creted renally  [6] . NT-proBNP levels are age and gender 
dependent and most likely related to the age-related de-
cline in the glomerular filtration rate  [7] .
 NT-proBNP has been described as a marker for ven-
tricular dysfunction and hypertrophy  [8] . Serum levels of 
natriuretic peptides correlate with elevated end-diastolic 
pressure and left ventricular wall tension as well as the 
New York Heart Association classification  [9–11] .
 In patients with precapillary pulmonary hyperten-
sion, serum NT-proBNP correlates with mean pulmo-
nary artery pressure and pulmonary vascular resistance 
 [12] , functional parameters of exercise tests (peak oxygen 
uptake, 6-min walking distance)  [13] and echocardio-
graphic indices of right ventricular dysfunction  [4] . NT-
proBNP has become a useful marker for the assessment 
of disease severity and therapeutic efficacy  [14] . In the 
treatment of patients with pulmonary hypertension, se-
rum levels of natriuretic peptides are often used to mon-
itor the course of the disease and adjust specific therapy 
 [15, 16] .
 Beside the interindividual influences of age, gender 
and renal function on serum levels, intraindividual dif-
ferences exist in the extent of secretion of natriuretic pep-
tides during a given cardiac load. Hermann et al.  [17] 
showed a significant elevation of serum NT-proBNP lev-
els immediately following a marathon in healthy runners 
in comparison with levels at rest. The influence of physi-
cal exercise on NT-proBNP serum levels was demonstrat-
ed in several studies in patients with chronic left heart 
failure, hypertensive cardiac disease and atrial fibrilla-
tion  [18–21] . In addition, in patients with left heart fail-
ure, a greater elevation of NT-proBNP serum levels than 
in healthy subjects was found after exercise, which cor-
related with a decreased left ventricular ejection fraction 
as an indicator of cardiovascular mortality  [22] .
 There is a lack of data regarding the influence of phys-
ical exercise on serum levels of natriuretic peptides in pa-
tients with precapillary pulmonary hypertension and 
right ventricular dysfunction.
 In this cross-sectional study, we examined the influ-
ence of physical exercise on NT-proBNP serum levels and 
the time course of this interaction.
 Patients and Methods 
 Patients 
 In this study, 20 hospitalized patients (nonsmokers; 9 male, 
11 female; mean age 55.3 years;  table 1 ) with mild to severe pre-
capillary pulmonary hypertension of different causes (idiopath-
ic, n = 13; chronic thromboembolic, n = 5; tissue associated, n = 
2) were examined. Inclusion criteria included cardiac recom-
pensation, sinus rhythm and normal serum creatinine and urea. 
Exclusion criteria were atrial fibrillation and left heart failure. 
No patient had an implantable device. Liver function and hemo-
globin values were normal. Patients were in New York Heart As-
sociation functional classes II (n = 6), III (n = 13) and IV (n = 1). 
In 9 patients, a specific therapy had been started before the 
study. All other patients had received only diuretics, and spe-
cific therapy was started after the diagnosis of pulmonary hy-
pertension. All examinations included in this study were per-
formed within 2 days.
 Hemodynamic and Exertional Parameters 
 A right heart catheter was inserted via the internal jugular 
vein (7.5-Fr Baxter  , Baxter Healthcare Corp., Irvine, Calif., 
USA). The following hemodynamic parameters were obtained: 
mean pulmonary artery pressure, pulmonary capillary wedge 
pressure, pulmonary vascular resistance, right atrial pressure, 
mean systemic pressure, central venous oxygen saturation, car-
diac output and cardiac index. In all patients, the Tei index (the 
Doppler-measured sum of isovolumetric contraction and relax-
ation time divided by the ejection time of the right ventricle  [23] ) 
was calculated by echocardiography of the right heart.
 On the second day, a 6-min walking distance test and cardio-
pulmonary exercise test were performed using a predefined 
schedule including time spans for rest ( table 2 ). Exertion at the 
anaerobic threshold, peak oxygen uptake, peak oxygen pulse (ox-
ygen uptake/heart frequency) and maximum systemic systolic 
pressure (peak RR) were measured.
 Measurement of NT-proBNP 
 Blood was drawn for measurements of serum NT-proBNP on 
day 2 at 5 defined time points at rest, at maximum exercise and 
during recovery ( table 2 ). Patients were asked to stay at relative 
rest in between. Light physical activity (standing up, slow walking 
up to 50 m) was allowed. Blood samples were kept at 4  °  C and cen-
trifuged at 3,300 rpm at 4  °  C for 10 min, and serum was stored at 
–70  °  C until being analyzed. Measurements of serum NT-proBNP 
concentrations were performed using a radioimmunoassay (Elec-
sys proBNP immunoassay, Roche Diagnostics, Basel, Switzer-
land) with a sensitivity of 88% and a specificity of 92%. The nor-
mal range is below 125 pg/ml.
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 Data Analysis 
 All data obtained were tested for normal distribution (Kol-
mogorov-Smirnov test), and means  8 SD were calculated. Sig-
nificant differences between two sequential NT-proBNP values 
were examined using the t test for paired samples. Relative chang-
es according to the base value at T1 (  ) were standardized with 
the following formula:
n
n 1
1
NT proBNP
NT-proBNP NT proBNP .
NT proBNP
 The interactions of exercise and right heart catheterization 
with serum values were examined using the Pearson correlation 
test. Statistical significance was accepted at p  ! 0.05. 
 Written informed consent was received from all patients for 
intravenous catheterization and obtaining blood samples. Both 
procedures were reviewed and accepted by the institutional re-
view board of the University of Leipzig, Faculty of Medicine.
 Results 
 The parameters of all patients are listed in  table 3 . Data 
are presented as mean values and SD. All parameters 
were found to be normally distributed (p  ! 0.05).
 Mean serum levels of NT-proBNP at the 5 time points 
(T1–T5) are shown in  table 4 . The NT-proBNP values of 
patient 10 differed widely from those of the remaining 
patients. In this patient, NT-proBNP increased from 
1,500 pg/ml at T1 to  1 10,000 pg/ml at T3 after light to 
severe physical exercise. According to the Dean-Dixon 
test for normally distributed samples, these values were 
identified as outliers (p  ! 0.001) and were therefore elim-
inated from the test group. A significant elevation of NT-
proBNP from rest to maximal physical exercise is appar-
ent (T1 to T3; p = 0.0002). Thirty minutes later (at T4), 
serum levels were decreasing (p = 0.0073). Values at T5 
(after 2 h of recovery following physical exercise) were not 
different from T4 (p = 0.3391).
Table 1.  Patients’ characteristics
Patient No.
(gender)
Age
years
Type of pulmonary 
hypertension
NYHA
class
BMI Specific therapy mPAP
mm Hg
VO2max
ml/min/kg
Tei 
index
1 (F) 27 CTEPH II 26.2 bosentan 41 12.2 0.24
2 (F) 41 IPAH II 24.4 bosentan 65 12.6 0.26
3 (M) 46 CTEPH III – 40 13.6 0.28
4 (F) 44 CTEPH III 23.18 – 44 15 0.24
5 (M) 66 IPAH III 23.14 – 44 9.6 0.28
6 (F) 70 tissue associated III 24.17 bosentan 47 10.2 0.25
7 (M) 68 IPAH II 22.6 – 51 13.4 0.23
8 (F) 58 CTEPH II 30.4 calcium channel antagonist 51 14.7 0.27
9 (M) 50 IPAH III 23.55 – 53 7.5 0.29
10 (M) 63 tissue associated III 25.3 – 45 7.1 0.23
11 (F) 63 IPAH III 30.7 sitaxsentan, calcium channel antagonist 68 9 0.23
12 (F) 42 IPAH III 38.6 sildenafil 77 10.3 0.27
13 (F) 65 IPAH II 28.4 bosentan, calcium channel antagonist 31 16 0.22
14 (M) 57 IPAH III 30.1 – 48 19.3 0.22
15 (F) 42 IPAH IV 35.4 sildenafil, bosentan 82 6.7 0.34
16 (M) 84 IPAH III 24.5 bosentan 40 11 0.29
17 (F) 71 CTEPH III 25.3 – 51 11.6 0.24
18 (M) 43 IPAH III 37.9 – 56 15.9 0.25
19 (M) 52 IPAH II 36.5 bosentan 60 10.5 0.25
20 (F) 54 IPAH III 29.4 – 57 13.4 0.27
NYHA = New York Heart Association; mPAP = mean pulmonary artery pressure; VO2max = peak oxygen uptake; CTEPH = chron-
ic thromboembolic pulmonary hypertension; IPAH = idiopathic pulmonary arterial hypertension; – = no specific therapy. 
Table 2. T ime points of NT-proBNP measurements within the 
exercise schedule
T1 at 6 a.m., at rest in bed
T2 at 10.30 a.m. (30 min after 6-min walking distance test)
T3 at maximum exercise (ergospirometry), 11 a.m.
T4 30 min after ergospirometry, at rest (recreation)
T5 120 min after ergospirometry, at rest
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 All absolute NT-proBNP values at rest (T1) and at 
maximum exercise (T3) are shown in  figure 1 (except pa-
tient 10). In all patients, except patient 8, an increase in 
serum levels from T1 to T3 was observed. Compared to 
values at rest (T1), a mean elevation of 24% (range 3–54%; 
  3 NT-proBNP) was found. In the patients of this study, 
serum levels at rest showed a mean 9-fold elevation (1.7- 
to 19-fold) compared to the given cutoff  [6] , while at the 
point of maximum exertion, a mean elevation of 11-fold 
was measured. In patient 13, the serum level at rest was 
within the normal range (77.7 pg/ml). Also in this patient, 
there was a significant elevation of the value presented at 
maximum exertion (103.2 pg/ml). Resting, i.e. baseline, 
serum levels were correlated with the hemodynamic pa-
rameters cardiac output and cardiac index as well as the 
exercise test parameters ( table 5 ). There was also a corre-
lation with the Tei index (p = 0.03). Resting NT-proBNP 
levels were not correlated with levels at maximum exer-
cise (p = 0.4393). However, a correlation between the in-
dividual relative changes and pulmonary vascular resis-
tance (p = 0.025), cardiac output (p = 0.015) and cardiac 
index (p = 0.003) was calculated.
 Discussion 
 The present study demonstrates elevation of serum 
NT-proBNP following physical exercise in patients with 
precapillary pulmonary hypertension. A significant in-
crease in NT-proBNP was seen in all but one patient (pa-
tient 8) at maximum exertion.
 After a 30-min period of relaxation (T4), a significant 
decrease in serum levels was measured in comparison to 
those at maximum exercise. The relative increase in NT-
proBNP from rest to exercise correlated with cardiac out-
put and pulmonary vascular resistance.
 All patients exhibited chronic right heart failure with 
right heart enlargement. We therefore expected elevated 
serum NT-proBNP levels in all patients  [11] . A mean 
9-fold increase in this marker was measured at rest com-
pared to the cutoff of the normal value for healthy sub-
jects.
 In one patient (patient 13), a normal resting serum lev-
el may be explained by the mild idiopathic pulmonary 
hypertension with only slightly increased pulmonary 
vascular resistance and a cardiac output of 4.9 liters/min. 
Nevertheless, a significant rise in NT-proBNP was also 
observed in this patient following exercise. The observa-
tion of right ventricular dysfunction without significant 
elevation of serum NT-proBNP was previously described 
in a retrospective study in 2007  [24] . Normal serum NT-
proBNP levels were found in 22 of 86 patients with mild 
to moderate precapillary pulmonary hypertension and a 
pathologic Tei index.
 As shown in  figure 1 in this study, a wide range of se-
rum levels at rest was observed, which most likely dem-
onstrates the differing extent of right ventricular dys-
function in our patients. However, the parameter of right 
ventricular function (Tei index) did not correlate well 
with NT-proBNP. In future investigations, right ventric-
ular mass will have to be focused or the measured values 
be referenced to body surface. Since we did not find ele-
vated creatinine values in these patients, reduced glomer-
Table 3.  Parameters of the 20 patients from echocardiography, 
ergospirometry and right heart catheterization
Parameters Mean 8 SD
Tei index 0.2680.03
Maximum exercise, W 69.8826.8
VO2max, ml/min/kg 1283.28
O2 pulse, ml/min/heart frequency 7.0982.36
EqCO2 at anaerobic threshold, mm Hg 50.16816.8
PaO2 at maximum exertion, kPa 8.281.5
mPAP, mm Hg 52.55812.82
PVR, dyns/cm5 999.28424.5
PC, mm Hg 9.583.1
CO, l/min 3.7581.02
CI 280.6
SvO2, % 64.489
VO2max = Peak oxygen uptake; EqCO2 = ventilatory equiva-
lent for carbon dioxide; PaO2 = partial pressure of oxygen in ar-
terial blood; mPAP = mean pulmonary artery pressure; PVR = 
pulmonary vascular resistance; PC = pulmonary capillary wedge 
pressure; CO = cardiac output; CI = cardiac index; SvO2 = central 
venous oxygen saturation.
Table 4.  NT-proBNP serum levels of 19 patients (excluding patient 
10) at the 5 measurement times (table 2)
Measurement time NT-proBNP, pg/ml
T1 1,2788998
T2 1,42681,110
T3 1,59281,219
T4 1,51881,170
T5 1,59781,266
Values are shown as means 8 SD.
 Grachtrup  /Brügel  /Pankau  /Halank  /
Wirtz  /Seyfarth  
Respiration 2012;84:454–460458
ular filtration rates should be considered as a possible 
source of variation.
 In this study we observed a clear dependence of NT-
proBNP serum levels on physical exercise. At maximum 
exercise, NT-proBNP levels were elevated by 24  8 18% 
compared to resting levels, which were already increased 
up to 23-fold over values of healthy controls. Statistical 
analyses demonstrated a significant correlation of the ex-
ercise-induced increase with cardiac output and pulmo-
nary vascular resistance.
 We tried to eliminate additional sources of variation. 
Blood samples were taken under standardized condi-
tions. The best interindividual comparability was ob-
served at time points T1–T3. At these time points, pa-
tients followed a well-defined schedule controlling the 
level of physical exercise. The level of control was not the 
same for subsequent time points. Despite hospitalization, 
3 patients did not get to rest in between T3 and T4, and 
about half of the patients did not strictly follow the sched-
ule between T4 and T5, which may have prevented a fur-
ther decrease in serum NT-proBNP at T5. However, tak-
ing into consideration the fact that the half-life of NT-
proBNP is approximately 120 min  [6] , elevation at T3 
could still have been caused by the slight exertion in the 
hours before and not only by the maximal exercise. The 
combined exercise tests performed within 1 h could have 
0
N
T-
p
ro
BN
P 
(p
g
/m
l)
1 2 3 4 5 6 7 8 9 11
Patient No.
12 13 14 15 16 17 18 19 20
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
T1 T3
Table 5.  Pearson correlations (p value/R value)
Tei index Maximum 
exertion
VO2max O2 pulse EqCO2 PaO2 mPAP PVR CO CI SvO2
NT-
proBNP1
S
(0.03/0.44)
S
(0.006/–0.56)
S
(0.009/–0.54)
S
(0.034/–0.43)
S
(0.003/0.6)
S
(0.02/–0.47)
NS
(0.48/–0.009)
NS
(0.103/0.3)
S
(0.002/–0.62)
S
(0.02/–0.49)
S
(0.03/–0.45)
3NT-
proBNP
NS
(0.35/0.1)
NS
(0.31/0.12)
NS
(0.04/–0.44)
NS
(0.37/0.08)
NS
(0.15/–0.25)
NS
(0.22/0.19)
NS
(0.1/0.31)
S
(0.025/0.45)
S
(0.0145/–0.5)
S
(0.0027/–0.61)
NS
(0.09/–0.32)
Tei index – S
(0.021/–0.47)
S
(0.002/–0.62)
NS
(0.12/–0.28)
NS
(0.08/0.33)
NS
(0.17/–0.23)
S
(0.04/0.41)
S
(0.04/0.41)
NS
(0.06/–0.37)
NS
(0.09/–0.33)
NS
(0.06/–0.37)
NT-proBNP1 = NT-proBNP at T1; 3NT-proBNP = relative change between T1 and T3; VO2max = peak oxygen uptake; EqCO2 = ventilatory equivalent for 
carbon dioxide; PaO2 = partial pressure of oxygen in arterial blood; mPAP = mean pulmonary artery pressure; PVR = pulmonary vascular resistance; CO = car-
diac output; CI = cardiac index; SvO2 = central venous oxygen saturation; S = significant; NS = not significant.
 Fig. 1. Absolute NT-proBNP levels in 19 
patients (excluding patient 10) at T1 and 
T3. 
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been the reason for the lack of a significant drop in serum 
levels at T5.
 A correlation of mean pulmonary artery pressure with 
the levels of NT-proBNP at rest was not observed in this 
study. Similarly, the individual increase in NT-proBNP 
levels following maximum exercise did not correlate with 
mean pulmonary artery pressure. However, resting se-
rum levels of NT-proBNP correlated with the Tei index 
and cardiac output and thus with the extent of right heart 
failure. This might support the consideration that the ex-
tent of right heart failure as indicated by NT-proBNP 
does not correlate with the level of pulmonary arterial 
pressure but is characterized by the cardiac output. Inter-
estingly, the Tei index did correlate slightly better with 
NT-proBNP at rest than with mean pulmonary artery 
pressure and pulmonary vascular resistance, but not with 
cardiac output. Since a relationship between body mass 
index (BMI) and NT-proBNP has been discussed  [25] , 
BMI was calculated in our patients ( table 1 ). It was nor-
mally distributed and did not show a significant corre-
lation with NT-proBNP in our patients (BMI vs. NT-
proBNP at rest: p = 0.055, r = –0.38; BMI vs.   3 NT-
proBNP: p = 0.067; r = 0.35). These findings are probably 
due to the small number of patients in this study.
 We observed a correlation of central venous oxygen 
saturation, peak oxygen uptake and peak oxygen pulse 
with NT-proBNP at rest. The change in NT-proBNP be-
tween T1 and T3 was not directly correlated with these 
parameters. Since NT-proBNP indicates the extent of 
right heart failure, lack of a relationship of the change in 
NT-proBNP with O 2 parameters only suggests that NT-
proBNP elevation is caused by multiple factors.
 In spite of the small number of patients in this study, 
we demonstrated acute effects of physical exercise on NT-
proBNP serum levels in patients with right heart failure. 
One patient, in our series labeled patient number 10, had 
to be excluded from further statistical evaluation. In this 
patient, very high serum levels were detected, suggesting 
considerable right heart failure during exercise. Howev-
er, even in this patient a significant increase in the NT-
proBNP serum level at T3 and a decrease following recov-
ery was observed, emphasizing the results of our study.
 For patients with pulmonary hypertension, even mild 
physical exercise such as standing tall, walking at normal 
speed and climbing stairs may represent great physical 
challenges involving increased load on the right ventricu-
lar muscle leading to increased cellular distension, which 
is the stimulus for the release of NT-proBNP into the 
serum, as is demonstrated here at T2 compared to rest-
ing conditions. A half-life of 120 min, renal elimination 
and bursts of secretion characterize the release of NT-
proBNP following even mild physical exercise. Serum 
NT-proBNP is therefore considered to be a useful diag-
nostic parameter for the evaluation of heart failure  [13–
16] . Values measured after mild physical exercise do not 
appear to be very useful for the accurate long-term fol-
low-up of patients with pulmonary hypertension. In or-
der to be able to compare intraindividual and interindi-
vidual values of patients, measurements should take into 
account that even mild physical exercise, as is involved in 
the patients coming into the physician’s office, may sig-
nificantly alter NT-proBNP levels. Based on the half-life 
of NT-proBNP, one might opt for a 2-hour period more 
or less devoid of physical activity, but our T5 value sug-
gests that even this might not be enough. We are well 
aware that these conditions are not easily applicable in the 
real world. Therefore, wider variation limits of serum lev-
els allow only an approximation of the extent of chronic 
(right) heart failure and should be used with caution and 
in addition to a distinct clinical examination, exercise 
tests and echocardiography. Given the costs of the exam-
ination, extensive application of this diagnostic instru-
ment should be avoided. Furthermore, studies involving 
hemodynamics at exercise with distinction of right and 
left heart failure are needed for a better understanding of 
the pathophysiologic basis of NT-proBNP elevation.
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